1 Min Read
April 24 (Reuters) - GlaxoSmithKline:
* FDA APPROVED EXPANDED INDICATION FOR TRELEGY ELLIPTA IN THE U.S. FOR TREATMENT OF PATIENTS WITH COPD Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.